Page 3 - Symphony Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Big data is transforming the real estate industry. Real estate developers and investors are able to now integrate disconnected data like never before to understand things like a location’s risks, opportunities, and pricing. For example, properties within a quarter-mile of two specialty grocery store leads to higher property values but being within four of these stores correlates to lower pricing. An insight like this could be uncovered manually but it would take countless hours of sorting through data while not even sure what you are looking for. Cherre is a real estate data management pla...

Kaia Health, a NYC-based digital therapeutics company, raised a $75m Series C funding round. The round was led by an unnamed growth equity fund with participation from existing investors Optum Ventures, Eurazeo, capital300, Balderton Capital, Heartcore Capital, Symphony Ventures (the investment vehicle of golf legend Rory McIlroy) and A Round Capital. The company, which has raised a total of $125m to date, intends to use the funds to grow its commercial team, accelerate product and partnership development and extend the offering within Europe. Led by CEO, President, and Founder Konstantin M...

Kaia Health Raises Funds, Plans Expansion Kaia Health announces it has raised $75 million in Series C funding (total raised to date: $125 million) to expand its clinical capabilities and transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and Europe. Fundraising was led by an unnamed leading growth equity fund with support from existing investors, including Optum Ventures, Eurazeo, capital300, Balderton Capital, Heartcore Capital, Symphony Ventures (investment vehicle of four times Major winner Rory McIlroy) and A Round Capit...

Published: Apr 29, 2021 By Alex Keown Less than one year after  launching, Ohio-based Forge Biologics  secured $120 million in a Series B financing round to support the clinical development of its gene therapy program for rare diseases, including the typically fatal Krabbe disease. In an announcement this morning, Forge said the proceeds from the Series B program will be used to accelerate the expansion of its AAV manufacturing CDMO capabilities with cGMP production capacity and operate its subsidiaries that are advancing novel AAV gene therapy programs. The company said it takes ...

April 29, 2021 April 29, 2021 | Illumina joins the Gates Foundation in a global pathogen genomics initiative, new money for immune profiling, and Benchling nets $200M for their cloud platform.   $375M: Fund for Growth-Stage Medtech, Digital Health  Endeavour Vision has closed Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning...